Publications
134
Citations
15,603
Est. group size
~18
Recurring co-author estimate
Active years
20
Publishing since 2007
Typically publishes in teams of ~26 · 5% small-team papers (≤3 authors) · across 25 venues
- Translating ctDNA into cutaneous melanoma care: An international expert survey
European Journal of Cancer · 2026
- ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in patients with Merkel cell carcinoma and lymph node metastases.
Journal of Clinical Oncology · 2026
- Nivolumab + relatlimab (NIVO + RELA) in advanced melanoma: 5-year update of RELATIVITY-047.
Journal of Clinical Oncology · 2026
- Nivolumab for Resected Stage III or IV Melanoma at 9 Years
New England Journal of Medicine · 2025
- Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus
Cancers · 2025
- 1619P Pooled outcomes with first-line nivolumab + relatlimab (NIVO + RELA) in patients (pts) with advanced melanoma (MEL)
Annals of Oncology · 2025
- Proceedings of the seventh annual Women in Melanoma Conference
Therapeutic Advances in Medical Oncology · 2025
- Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer
UNC Libraries · 2025
- Résultats poolés de l’association nivolumab + relatlimab (NIVO + RELA) en première ligne chez les patients atteints d’un mélanome avancé
Annales de Dermatologie et de Vénéréologie - FMC · 2025
- Supplementary Data 1 from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
2025
- Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238
Journal of Clinical Oncology · 2024
- The impact of cancer metastases on COVID‐19 outcomes: A COVID‐19 and Cancer Consortium registry‐based retrospective cohort study
Cancer · 2024
- Data from Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238
2024
- Supplementary Data 1 from Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238
2024
- Supplementary Data 1 from Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238
2024
- Journal of Clinical Oncology×14
- Journal for ImmunoTherapy of Cancer×6
- JAMA Network Open×4
- The Lancet Oncology×3
- Annals of Oncology×3
- Douglas B. Johnson
Medicine · University of Michigan
- Christopher D. Lao
Medicine · University of Michigan
- Siming Li
Medicine · University of Michigan
- Kari Kendra
Medicine · The Ohio State University
- Jiayi Yu
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile